For filings with the FCA include the annex |
|
For filings with issuer exclude the annex |
|
|
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
|
|
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii |
Allergy Therapeutics plc |
2 Reason for the notification (please tick the appropriate box or boxes): |
An acquisition or disposal of voting rights |
|
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
An event changing the breakdown of voting rights |
X |
Other (please specify): |
|
|
3. Full name of person(s) subject to the
notification obligation: iii |
Abbott Laboratories |
4. Full name of shareholder(s)
(if different from 3.):iv |
CFR lnternational SpA Yissum Holding Limited |
5. Date of the transaction and date on
which the threshold is crossed or
reached: v |
20 November 2015 |
6. Date on which issuer notified: |
20 November 2015 |
7. Threshold(s) that is/are crossed or
reached: vi, vii |
Below 41% |
8. Notified details: |
A: Voting rights attached to shares viii, ix |
Class/type of
shares
if possible using
the ISIN CODE
|
Situation previous
to the triggering
transaction |
Resulting situation after the triggering transaction |
Number
of
Shares |
Number
of
Voting
Rights |
Number
of shares |
Number of voting
rights |
% of voting rights x |
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
Ord GBP 0.01 |
240,584,571 |
240,584,571 |
|
|
240,584,571 |
|
40.995% |
GB00B02LCQ05 |
|
B: Qualifying Financial Instruments |
Resulting situation after the triggering transaction |
Type of financial
instrument |
Expiration
date xiii |
Exercise/
Conversion Period xiv |
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted. |
% of voting
rights |
|
|
|
|
|
|
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
Resulting situation after the triggering transaction |
Type of financial
instrument |
Exercise price |
Expiration date xvii |
Exercise/
Conversion period xviii |
Number of voting rights instrument refers to |
% of voting rights xix, xx |
|
|
|
|
|
Nominal |
Delta |
|
|
|
Total (A+B+C) |
Number of voting rights |
Percentage of voting rights |
240,584,571 |
40.995% |
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi |
Through a series of controlled undertakings, Abbott Laboratories has an indirect holding of 99.9% of the shares in CFR Pharmaceuticals, SA. CFR Pharmaceuticals SA's wholly owned subsidiary, CFR International SPA, holds 17.567% of the voting rights in Allergy Therapeutics plc directly and 23.428% of the voting rights in Allergy Therapeutics plc indirectly. CFR International SPA also has a 100% interest in Yissum Holding Limited, which directly holds 23.428% of shares in Allergy Therapeutics plc. |
|
Proxy Voting: |
10. Name of the proxy holder: |
|
11. Number of voting rights proxy holder will cease
to hold: |
|
12. Date on which proxy holder will cease to hold
voting rights: |
|
|
13. Additional information:
|
|
14. Contact name: |
Des Peters |
15. Contact telephone number: |
+1 224-667-6545 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|